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minute/1.73m2, respectively). CONCLUSION: This analysis
identiﬁed a signiﬁcant decrease in GFR over time. Persons with
controlled BP taking antihypertensive therapy had higher GFR
than those taking no medication suggesting that antihypertensive
medication use preserves kidney function.
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OBJECTIVE: Failure to dose adjust for renal insufﬁciency during
hospitalization can be a common cause for medication errors and
are an important function for clinicians. We examined the preva-
lence, mortality and length of stay (LOS) for cases that exhibited
changes in renal function during hospitalization. METHODS:
We retrospectively analyzed 1,011,055 non-dialysis admissions
who had at least two serum creatinine values during hospital stay
across 74 hospitals that provided electronic laboratory results
from 2003–2006. We used a modiﬁed Cockcroft-Gault (140-
age)/SCr (x 0.85 for females) to determine baseline and changing
creatinine clearance (eCrCl, ml/min). Cases were stratiﬁed based
on eCrCl as normal ( 81 ml/min), mild (50–80 ml/min), mod-
erate (16–49 ml/min), and advanced (15 ml/min). Worsening
or improvement was deﬁned as cases that moved one or more
eCrCl strata to another during hospitalization. Unadjusted hos-
pital mortality (95% CI) and median LOS were evaluated.
RESULTS: On admission 29.6% had normal, 34.4% had mild,
34.1% had moderate, and 1.9% had advanced eCrCl. Of these
cases the eCrCl remained the same in 79.2%, worsened in 11.6%
and improved in 9.2%. Mortality and median LOS was highest
for worsening eCrCl (7.9 [CI:7.8–8.1] and 6 days) followed by
those remaining the same (2.8 [CI:2.8–2.9] and 4 days) and those
with improving eCrCl (1.8 [CI:1.7–1.9] and 4 days). Cases with
 2 strata worsening in eCrCl (0.5% of cases) had higher mor-
tality and LOS (25.9 [CI:24.7–27.1] and 10 days) than those
with moderate (5.0 [CI:4.9–5.1] and 5 days, 28.8% of cases) or
advanced (13.3 [CI:12.7–13.8] and 5 days, 1.5% of cases) eCrCl
that remained the same. CONCLUSION: Both improvement and
worsening renal function necessitating potential dosage adjust-
ment are common during hospitalization. Mortality and LOS is
higher for cases that had worsening renal function. Comprehen-
sive renal dosing programs have the potential of improving medi-
cation safety and related outcomes.
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OBJECTIVE: The treatment of chronic kidney disease (CKD)
with dialysis is associated with the appearance of hyperphos-
phatemia, which contributes to the presence of vascular calci-
ﬁcations, thus increasing the probability of the occurrence of
cardiovascular events and death in these patients. The objective
of this analysis was to evaluate the incremental cost-
effectiveness of the use of sevelamer to manage hyperphos-
phatemia secondary to CKD from an institutional perspective.
METHODS: A Markov model was created in TreeAge to esti-
mate the costs and beneﬁts of the treatment with sevelamer or
calcium tablets in patients with renal failure considering a tem-
porary horizon of 60 months. The transition probabilities were
taken from clinical trials identiﬁed through a systematic review
of literature. The effectiveness measure considered was an
increase in patient survival. Data related to the use of resources
were obtained from a nominal group and cost information was
obtained from price lists and rates published by health institu-
tions. In addition a univariate sensitivity analysis was per-
formed on the probability of death for sevelamer group. Costs
were estimated using 2007 prices and are expressed in US
dollars (exchange rate of 10.93 pesos per US dollar).
RESULTS: Survival of patients with CKD increased in 18.4%
in the sevelamer group, compared to the calcium group
(83.12% vs. 64.72%). The expected average monthly cost
was $639 for calcium and $989.50 for sevelamer. The Cost-
Effectiveness Ratio of sevelamer and calcium was $1068 and
$777.70, respectively, and the Incremental Cost-Effectiveness
Ratio for the implementation of sevelamer vs. calcium was
$3343.50. CONCLUSION: Sevelamer is a cost-effective drug
for the treatment of hyperphosphatemia in patients with
chronic kidney disease in the Mexican context.
PUK5
COST-EFFECTIVENESS OF CINECALCET INTHETREATMENT
OF SECONDARY HYPERPARATIROIDISM (SHPT)
Pinto CG1,Weigert A2, Pissarra I3, Paquete AT4
1Instituto Superior de Economia e Gestão,Technical University of
Lisbon, Lisboa, Portugal, 2Santa Cruz Hospital, Carnaxide, Portugal,
3Instituto de Medicina Preventiva, Lisboa, Portugal, 4Research Centre
on the Portuguese Economy—CISEP, Lisboa, Portugal
OBJECTIVE: To determine the incremental cost-effectiveness
ratio (ICER) of cinacalcet as an adjuvant therapy for SHPT
from the perspective of the Portuguese NHS. METHODS: A
probabilistic Markov model was used to compare best standard
care (BSC) with BSC plus cinacalcet. The model was developed
in cycles of six months until the death of all patients. Patients
were distributed according to the risk of hospital admission due
to cardiovascular events, major or minor fractures and parathy-
roidectomies. The absence of events and/or death was also
considered. The probabilities of SHPT’s complications were
obtained from the literature. Portuguese ofﬁcial mortality rates
were weighted by the presence of renal insufﬁciency and by the
PTH levels. Due to lack of alternative, the resources used (only
direct medical costs) were estimated by a Delphi panel of eight
nephrologists and by a physical medicine and rehabilitation
specialist. Unit costs were obtained from Portuguese ofﬁcial
sources. Market shares of medicines prescribed in outpatient
services were selected from the IMS. RESULTS: Cinacalcet
increases 0.4 life years (LY) per patient with SHPT. The use of
cinacalcet saves hospital admissions and follow-up costs of sec-
ondary events, but is associated with an ICER of €53,682 per
LY gained. However, if dialysis costs are not considered, the
ICER is €32,374 per LY gained and the probability of being
cost-effective increases from 61% to 83% if acceptability for
reimbursement is limited at €50.000 per LY gained. CONCLU-
SION: Using a €50,000 WTP threshold, cinacalcet was found
cost-effective if the increased cost of dialysis was excluded. The
inclusion of this cost (induced by a longer life expectancy) leads
to an ICER of €53,682 per LY gained. A clear paradox arises
here as the alternative becomes less cost-effective by increasing
dialysis patients’ longevity.
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